TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8991237

Group type: EXPERIMENTAL
Intervention: Combined yellow fever and measles vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yellow fever vaccine administered separately
Number of subjects: 0

Group type: COMPARATOR
Intervention: Measles vaccine administered separately
Number of subjects: 0
Study: 1322512

Group type: EXPERIMENTAL
Intervention: 3 mg subcutaneous sumatriptan
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 6412265

Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 0
Study: 29948103

Group type: EXPERIMENTAL
Intervention: Overnight treatment with the occlusive intensive patch (OIP) containing Allium cepa extract and allantoin for 12-24 weeks
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Overnight treatment with the occlusive intensive patch (OIP)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Subject- and investigator-evaluated Global Aesthetic Improvement Scale scores for treated scars
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Global comfort of the OIP
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Safety of the OIP
Number of subjects: 125

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 125
Study: 29141661

Group type: EXPERIMENTAL
Intervention: Video Feedback Intervention to Promote Positive Parenting and Sensitive Discipline (VIPP-SD)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 300
Study: 26329980

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40-100 mg/day)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 24320833

Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Nutrition education course
Number of subjects: 143
Study: 21436335

Group type: EXPERIMENTAL
Intervention: Wingspan stent placement for MCA stenosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wingspan stent placement for other stenosis
Number of subjects: 60
Study: 18193377

Group type: EXPERIMENTAL
Intervention: Phytosterol enriched drinkable yogurt (1.6 g of free sterol equivalents)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Plain low-fat yogurt (control)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Phytosterol enriched drinkable yogurt
Number of subjects: 83
Study: 16644440

Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography (TTDE)
Number of subjects: 52
Study: 14598036

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic psychotherapy
Number of subjects: 70
Study: 11140432

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) administered via dry powder and metered-dose inhalers
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 13
Study: 8872851

Group type: EXPERIMENTAL
Intervention: Initial treatment with felodipine
Number of subjects: 411

Group type: COMPARATOR
Intervention: Low-dose felodipine
Number of subjects: 411

Group type: COMPARATOR
Intervention: High-dose felodipine plus additional drugs
Number of subjects: 411
Study: 1511150

Group type: EXPERIMENTAL
Intervention: Feedback on sampling quality evaluation in laboratory protocols
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Specific advice on indication
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Monthly performance overviews comparing individual doctors to peers
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Combined spatula and Cytobrush method
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Request for further information, help, or training
Number of subjects: 179
Study: 6595452

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10,000 IU daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation after switching from placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30554409

Group type: EXPERIMENTAL
Intervention: High serum levels of NOx over 70 µmol/L
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: High serum levels of NOx over 70 µmol/L in men
Number of subjects: 1869
Study: 29505803

Group type: EXPERIMENTAL
Intervention: 10-Hz excitatory rTMS to the rIFG at 100% motor threshold with 900 pulses per session
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-controlled condition
Number of subjects: 20
Study: 25503483

Group type: EXPERIMENTAL
Intervention: Online journal writing intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High disclosure of negative emotions during journaling
Number of subjects: 0
Study: 25541919

Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg every 6 hours) intravenously for fifteen days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 58
Study: 21725375

Group type: EXPERIMENTAL
Intervention: Early hospital discharge (Arm A)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard hospital-based follow-up (Arm B)
Number of subjects: 131
Study: 19947262

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Shenshu (BL 23), Guanyuan (CV 4), Taixi (KI 3), Sanyinjiao (SP 6) for 12 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Oral administration of Polyene Phosphatidylcholine Capsules for 12 weeks
Number of subjects: 98
Study: 17537866

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 5 days
Number of subjects: 469

Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 469
Study: 15277269

Group type: EXPERIMENTAL
Intervention: Study recommendations for boost radiation treatment
Number of subjects: 248

Group type: COMPARATOR
Intervention: Stated policy for boost radiation treatment
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Invasive disease at a resection margin
Number of subjects: 248
Study: 11455677

Group type: EXPERIMENTAL
Intervention: Enteric coated formulation containing 90 mg peppermint oil and 50 mg caraway oil (test)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate release formulation containing 36 mg peppermint oil and 20 mg caraway oil (reference)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enteric coated formulation (test)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate release formulation (reference)
Number of subjects: 16
Study: 9744605

Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine (0.125 mg/tablet, 2 tablets)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 8688342

Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2272214

Group type: EXPERIMENTAL
Intervention: Dietary history method
Number of subjects: 194

Group type: COMPARATOR
Intervention: 3-day food record
Number of subjects: 194
Study: 115193

Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: pimozide
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 31896122

Group type: EXPERIMENTAL
Intervention: Innovations originating within the unit linked to the availability of new technology
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Availability of new knowledge or technology
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Guidelines or regulations from outside the unit
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Need to standardize practices
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Participation in research
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Occurrence of adverse events
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Wish to improve care
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Reported changes concerning ventilation, feeding and nutrition, neonatal sepsis, infant care, pain management and care of parents
Number of subjects: 44
Study: 30690687

Group type: EXPERIMENTAL
Intervention: Adjuvant RT alone (n=646)
Number of subjects: 3489

Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based CT alone (n=705)
Number of subjects: 3489

Group type: EXPERIMENTAL
Intervention: Combined adjuvant RT and anthracycline-based CT (n=1025)
Number of subjects: 3489

Group type: COMPARATOR
Intervention: No treatment (n=1113)
Number of subjects: 3489
Study: 26273852

Group type: EXPERIMENTAL
Intervention: Negative mood during retrieval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood at both encoding and retrieval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study: 24043481

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 21679588

Group type: EXPERIMENTAL
Intervention: Live tissue training (animal model group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simulator training (simulator group)
Number of subjects: 24
Study: 19220889

Group type: EXPERIMENTAL
Intervention: Qualitative research on parents' experiences of trial recruitment
Number of subjects: 0
Study: 16720926

Group type: EXPERIMENTAL
Intervention: Prophylactic tropisetron
Number of subjects: 288

Group type: COMPARATOR
Intervention: Rescue tropisetron
Number of subjects: 288
Study: 15301778

Group type: EXPERIMENTAL
Intervention: External loads of 19 kg with antagonistic co-contraction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: External loads of 38 kg with antagonistic co-contraction
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: External stiffness of 4.9 kN/m
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: External stiffness of 8.1 kN/m
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mean intrinsic stiffness
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Reflex gain
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Constant reflex delay
Number of subjects: 13
Study: 11771442

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted colectomy (LAC)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 1200
Study: 9103468

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 2 min before endotoxin challenge
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) 25 microg/kg administered 1 hour after endotoxin challenge
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (rhIL-10) administered both before and after endotoxin challenge
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 16
Study: 1531818

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 2859409

Group type: EXPERIMENTAL
Intervention: Paternal cells (purified lymphocytes from husbands' blood)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Own cells (purified lymphocytes from their own blood)
Number of subjects: 49
Study: 31358708

Group type: EXPERIMENTAL
Intervention: Non-resorbable GTR membrane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioabsorbable GTR membrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 28980166

Group type: COMPARATOR
Intervention: Intermittent cefotaxime dosing regimens
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefotaxime at 100 mg·kg-1·day-1
Number of subjects: 49
Study: 27566961

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Specialist supportive clinical management (SSCM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 56
Study: 24338947

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (cognitive-behavioral therapy and/or psychopharmacology)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004
Study: 22569436

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg every other day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21169102

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 32
Study: 17611834

Group type: EXPERIMENTAL
Intervention: 90‐min interval training program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest in sitting position for 90 min
Number of subjects: 12
Study: 15675576

Group type: COMPARATOR
Intervention: 5‐FU alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐FU+cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer agents (TS‐1, CPT‐11, docetaxel, paclitaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPT‐11 and paclitaxel-based regimens
Number of subjects: 0
Study: 12386077

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Lubricant)
Number of subjects: 25
Study: 10445304

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 178
Study: 7798503

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with streptokinase, recombinant tissue-type plasminogen activator, or anistreplase plus intravenous heparin (5,000 IU bolus followed by 1,000 U/h infusion)
Number of subjects: 43
Study: 2119263

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study: 6118380

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene preparation (Doleron novum)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Codeine preparation (Staralgin)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 94
Study: 31767717

Group type: EXPERIMENTAL
Intervention: 3g oral fosfomycin tromethamine every other day (QOD) for 3 doses and then every day (QD) for 7 doses
Number of subjects: 18
Study: 27860267

Group type: EXPERIMENTAL
Intervention: RN317 (s.c. 3.0 mg/kg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Bococizumab (s.c. 3.0 mg/kg)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multiple-dose RN317 (s.c. 300 mg every 28 days; three doses)
Number of subjects: 133
Study: 24967824

Group type: EXPERIMENTAL
Intervention: Topical application of Tranexamic acid (TXA) postoperatively, diluted to 0.2% concentration, gargled or sprayed 5-6 times daily from postoperative day 5-10.
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group (no TXA application)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Topical application of Tranexamic acid (TXA) postoperatively
Number of subjects: 494
Study: 23110312

Group type: EXPERIMENTAL
Intervention: Fibermalt 45 g/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fibermalt 60 g/d
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (0 g/d)
Number of subjects: 29
Study: 21859366

Group type: EXPERIMENTAL
Intervention: Iron(III) polymaltose complex (Maltofer(®)) 100 mg iron twice daily for 90 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ferrous sulfate 100 mg iron twice daily for 90 days
Number of subjects: 80
Study: 19057424

Group type: EXPERIMENTAL
Intervention: Radiosurgery (RS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-radiated (RS)
Number of subjects: 21
Study: 16897119

Group type: EXPERIMENTAL
Intervention: Electrical stimulation program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biofeedback‐assisted isometric exercises
Number of subjects: 50
Study: 15215110

Group type: EXPERIMENTAL
Intervention: BAL5788 (750 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BAL5788 (125, 250, 500, 750, and 1,000 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11521989

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (400 mg b.i.d.)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9670986

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsensitized controls
Number of subjects: 0
Study: 8168039

Group type: COMPARATOR
Intervention: CMF regimen (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: DES-CMF (CMF preceded by diethylstilbestrol 1 mg orally per day for 3 days)
Number of subjects: 163
Study: 3233520

Group type: EXPERIMENTAL
Intervention: 6-hour teacher training workshop on child sexual abuse prevention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Post-only vignettes measure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6-week follow-up period
Number of subjects: 45

Group type: COMPARATOR
Intervention: Behavioral dimensions (reporting suspected abuse cases)
Number of subjects: 45
Study: 31077751

Group type: EXPERIMENTAL
Intervention: Vitamin D tablet, 1000IU/day (N=180; 69 boys, 111 girls)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Vitamin D fortified milk consumption, 200 ml/day, 40IU/100 ml (N=189; 93 boys, 96 girls)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Control (educational awareness) (N=166; 81 boys, 85 girls)
Number of subjects: 535
Study: 28865716

Group type: EXPERIMENTAL
Intervention: Risperidone maintenance treatment for 1 year
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Risperidone treatment length
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Duration of illness
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Baseline remission patients
Number of subjects: 374
Study: 25878120

Group type: EXPERIMENTAL
Intervention: High doses of imatinib combined with reduced-intensity chemotherapy (arm A)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard imatinib/hyperCVAD therapy (arm B)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 268
Study: 23568000

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention (n = 68)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care (control group, n = 58)
Number of subjects: 138
Study: 21422934

Group type: EXPERIMENTAL
Intervention: Elastoplast bandaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double tubigrip bandage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No support
Number of subjects: 0
Study: 18424596

Group type: EXPERIMENTAL
Intervention: Shallot flesh (99.2% quercetin glucosides and 0.8% quercetin aglycone)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Dry shallot skin (83.3% quercetin aglycone and 16.7% quercetin glucosides)
Number of subjects: 9
Study: 16877377

Group type: EXPERIMENTAL
Intervention: Daily 112.5 IU recombinant FSH from cycle day 2-6 (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily 112.5 IU recombinant FSH from cycle day 7-11 (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group A (CD 2-6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B (CD 7-11)
Number of subjects: 0
Study: 12508146

Group type: EXPERIMENTAL
Intervention: IC14 (anti-CD14 antibody)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11789188

Group type: EXPERIMENTAL
Intervention: TCM-WM group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chemotherapy group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 8829932

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia with nitrous oxide (induced with thiopentone 6 mg kg‐1, maintained with halothane 1% and nitrous oxide 66% in oxygen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia with propofol-alfentanil (induced with alfentanil 25 micrograms kg‐1 and propofol 2 mg kg‐1, maintained with alfentanil and propofol infusions)
Number of subjects: 50
Study: 2056774

Group type: EXPERIMENTAL
Intervention: Aclarubicin (ACR) 75 mg/m2 daily for 3 days plus cytosine arabinoside (ara‐C) 100 mg/m2 per day for 7 days
Number of subjects: 180

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 45 mg/m2/day for 3 days plus ara‐C for 7 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Aclarubicin (ACR) plus ara‐C
Number of subjects: 180

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) plus ara‐C
Number of subjects: 180
Study: 6601847

Group type: EXPERIMENTAL
Intervention: sulfadimidine (1 g four times daily for seven days)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: tetracycline (500 mg four times daily for seven days)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole (TMP‐SMZ; 160 mg of TMP and 800 mg of SMZ twice daily for seven days)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: doxycycline (300 mg as a single dose)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: TMP‐sulfametrole (640 mg of TMP and 3,200 mg of sulfametrole once as a single dose)
Number of subjects: 151
Study: 30032464

Group type: EXPERIMENTAL
Intervention: Smartphone-based upper airway exercises (15 min of daily gameplay)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (5 s of daily voice recording)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 28115223

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Rotacaps/Rotahaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via Diskus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination 50/250 μg (FSC) via either inhaler
Number of subjects: 0
Study: 26769830

Group type: EXPERIMENTAL
Intervention: CrossFit training for 3 months
Number of subjects: 0
Study: 24268861

Group type: EXPERIMENTAL
Intervention: Daily multivitamin
Number of subjects: 14641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study: 21121981

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 5.0 × 10⁷ CFU/g, daily intake of 3.4 × 10⁹ CFU for 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no LGG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 39